论文部分内容阅读
目的观察培美曲塞联合顺铂/卡铂一线治疗晚期非鳞状非小细胞肺癌(NSCLC)的疗效和不良反应。方法选择晚期非鳞状NSCLC初治患者38例,一线进行培美曲塞联合顺铂或卡铂化疗:培美曲塞500mg/m2 d1,联合顺铂25mg/m2 d1～d3或卡铂(AUC=5)d1,每3周为1个周期重复,所有患者接受至少2个周期化疗。结果 38例可评价,CR 0例,PR 10例,SD 20例,PD 8例,客观有效率26.3%,疾病控制率78.9%,临床受益反应率为71.1%;主要不良反应为骨髓抑制、胃肠道反应,经对症处理后均能耐受。结论培美曲塞联合顺铂/卡铂一线治疗晚期非鳞状NSCLC疗效较好,不良反应轻微,易于耐受。
Objective To observe the efficacy and adverse reactions of pemetrexed combined with cisplatin / carboplatin in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Methods Thirty-eight patients with newly diagnosed non-squamous NSCLC were enrolled in this study. Pemetrexed combined with cisplatin or carboplatin was given in the first-line chemotherapy: pemetrexed 500mg / m2 d1 combined with cisplatin 25mg / m2 d1-d3 or carboplatin = 5) d1, repeated every 3 weeks for 1 cycle, and all patients received at least 2 cycles of chemotherapy. Results 38 cases were evaluable, CR 0 cases, PR 10 cases, SD 20 cases, PD 8 cases, the objective effective rate was 26.3%, the disease control rate was 78.9%, the clinical benefit response rate was 71.1%; the main adverse reactions were myelosuppression, stomach Intestinal reaction, after symptomatic treatment can tolerate. Conclusion Pemetrexed combined with cisplatin / carboplatin first-line treatment of advanced non-squamous NSCLC better efficacy, minor adverse reactions, easy to tolerate.